Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.66 |
| ▸ | TP53 | P04637 | 7/20 | 0.66 |
| ▸ | HTT | P42858 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.66 |
| ▸ | USP2 | O75604 | 3/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | COMT | P21964 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.45 |
| ▸ | MMP14 | P50281 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6051226 | 0.85 | PIK3CD (0.59) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| SCHEMBL27584879 | 0.84 | PIK3CD (0.57) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| SCHEMBL8344547 | 0.84 | KDM4E (0.60) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| SCHEMBL13474700 | 0.81 | PIK3CD (0.55) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| SCHEMBL13625051 | 0.81 | HSP90AA1 (0.66) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| Broxyquinoline SCHEMBL115293 | 0.80 | KDM4E (1.00) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| Broxyquinoline SCHEMBL29607319 | 0.80 | KDM4E (1.00) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| Broxyquinoline SCHEMBL30485535 | 0.80 | KDM4E (1.00) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| Broxyquinoline SCHEMBL31157810 | 0.78 | KDM4E (0.96) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 | |
| Broxyquinoline SCHEMBL22734870 | 0.78 | KDM4E (0.96) | KDM4EHSP90AA1TP53HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | KDM4E 2823/4885HSP90AA1 485/4885TP53 10/4885 |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | KDM4E 3604/4885HSP90AA1 1187/4885TP53 2906/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | KDM4E 3604/4885HSP90AA1 1187/4885TP53 2906/4885 |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | TERT, TERF2, RNGTT | KDM4E 1300/4885HSP90AA1 1080/4885TP53 400/4885 |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM4E 4624/4885HSP90AA1 1181/4885TP53 3870/4885 |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM4E 4624/4885HSP90AA1 1181/4885TP53 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.